Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DEVA-OV4
- Development stage
- Preclinical
- Lead developer
- Devacell
- Modality
- Gene Silencing → Gene Therapies, Oncolytic Viruses → Oncolytic Therapeutics, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies
- Administration
- Intravenous
01
Overview
**DEVA-OV4** is a preclinical DevaCell oncolytic cancer immunotherapy candidate based on the proprietary ONCoat™ synthetic-vector platform. It is described as an oncolytic vector program incorporating checkpoint-modulating, cytokine, and metabolic-enzyme payload components to promote tumor-cell killing and enhance antitumor immune responses in solid tumors; the individual checkpoint targets, cytokines, and metabolic enzyme have not been publicly specified. ([devacell.com](https://devacell.com/pipeline/))
- Other names
- DEVAOV4DEVAOV-4DEVAOV 4
Beyond the preview
Go deeper on DEVA-OV4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DEVA-OV4.